The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Glintborg, D., Christensen, L. L., Kvorning, T., Larsen, R., Højlund, K., Brixen, K., HOUGAARD, D. M., Handberg, A., & Andersen, M. (2015) · PubMed · doi:10.3109/00365513.2015.1074274 · Cited by 8
Blankfield, R. P. (2011) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2010-1369 · Cited by 8
Inherited antithrombin deficiency and anabolic steroids
Choe, H. K., Elfil, M., & DeSancho, M. T. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000454 · Cited by 8
The treatment of late-onset hypogonadism
Üçer, O., & Gumus, B. (2014) · Urology Research and Practice · doi:10.5152/tud.2013.97752 · Cited by 8
Glueck, C. J., Goldenberg, N., & Wang, P. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000637 · Cited by 9
Clavell-Hernández, J., & Wang, R. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.17050 · Cited by 8
Osadnik, T., Pawlas, N., Osadnik, K., Bujak, K., Góral, M., Lejawa, M., Fronczek, M., Reguła, R., Czarnecka, H., Gawlita, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215302 · Cited by 8
Use, Misuse, and Abuse of Androgens
Handelsman, D. J. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_44 · Cited by 8
Research on the steroidogenesis of proliferated Leydig cells in vitro
Zhong, L., Sun, J., Liu, G., Zhu, Y., & Zhu, J. (2013) · Journal of Artificial Organs · doi:10.1007/s10047-012-0684-y · Cited by 8
Anaissie, J. E., Pastuszak, A. W., & Khera, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00012-3 · Cited by 8
Testosterone, HDL and cardiovascular risk in men: the jury is still out
Rubinow, K. B., & Page, S. T. (2012) · Clinical Lipidology · doi:10.2217/clp.12.38 · Cited by 8
Parmar, R. P., Cronen, A. M., Hui, C. H., Stickels, M. W., Lederman, E. S., & Shah, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041341 · Cited by 7
Huang, X., Dong, P., Xu, Y., Ling, Y., Tan, S., Bai, Z., Shen, S., Lyu, J., & Wang, H. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70420 · Cited by 7
Zhang, X., Huang, K., Saad, F., Haider, K. S., Haider, A., & Xu, X. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0015 · Cited by 7
Ugo-Neff, G., & Rizzolo, D. (2022) · JAAPA · doi:10.1097/01.jaa.0000824956.78048.ff · Cited by 7
Natriuretic peptide testing strategies in heart failure: A 2023 update
Chaikijurajai, T., Rincon-Choles, H., & Tang, W. H. W. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.005 · Cited by 7
Antonič, K. G., & Zitzmann, M. (2023) · The Aging Male · doi:10.1080/13685538.2023.2296460 · Cited by 7
Estradiol, via estrogen receptor β signaling, mediates stress-susceptibility in the male brain
Georgiou, P., Postle, A. F., Mou, T.-C. M., Potter, L. E., An, X., Zanos, P., Patton, M. S., Pultorak, K. J., Clark, S. M., Ngyuyen, V., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03027-8 · Cited by 8
Enclomiphene Citrate Stimulates Serum Testosterone in Men With Low Testosterone Within 14 Days
Wiehle, R. D., Fontenot, G. K., Willett, M. S., Garcia, W. D., & Podolski, J. S. (2014) · Journal of Men s Health · doi:10.1089/jomh.2014.0006 · Cited by 7
Serum testosterone level correlates with left ventricular hypertrophy in older women
Szadkowska, I., Guligowska, A., Jegier, A., Pawlikowski, M., Pisarek, H., Winczyk, K., & Kostka, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1079043 · Cited by 7
Assessment and management of older people with sarcopenia
Roberts, H. C., Lowry, A. F., & Sayer, A. A. (2014) · Nursing Older People · doi:10.7748/nop.26.5.18.e556 · Cited by 7
A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men
Scovell, J. M., Ramasamy, R., & Kovac, J. R. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.1962 · Cited by 7
Effects of Testosterone Levels on Functional Recovery with Rehabilitation in Stroke Patients
Momosaki, R., Abo, M., Watanabe, S., Kakuda, W., Yamada, N., & Mochio, K. (2014) · Neurologia medico-chirurgica · doi:10.2176/nmc.oa.2014-0078 · Cited by 7
Saad, F., Haider, A., Giltay, E. J., & Gooren, L. J. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.081 · Cited by 7
Kula, K., & Słowikowska‐Hilczer, J. (2012) · Cited by 7
Benefits and Consequences of Testosterone Replacement Therapy: A Review
Polackwich, A. S., Tadros, N. N., Ostrowski, K. A., Resident, U., & Resident, U. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.59 · Cited by 7
Gan, E. H., & Quinton, R. (2016) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2016.307 · Cited by 7
Hypogonadism in Systemic Diseases
Rochira, V. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_28-1 · Cited by 7
Reconsideration of frailty in relation to surgical indication
Maeda, K., & Saiki, Y. (2017) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-017-0869-7 · Cited by 7
Testosterone replacement therapy: Dilemmas and challenges in China and Asia
Gu, Y., & An, Q. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_16_17 · Cited by 7
An analysis of online content related to testosterone supplementation
Sehn, E., Mozak, C., Yuksel, N., & Sadowski, C. A. (2018) · The Aging Male · doi:10.1080/13685538.2018.1482867 · Cited by 7
Clinical Update on Nursing Home Medicine: 2011
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.08.007 · Cited by 7
Testosterone Therapy: Increase in Hematocrit is Associated with Decreased Mortality
Strange, R. C., König, C. S., Ahmed, A., Hackett, G. I., Haider, A., Haider, K. S., Desnerck, P., Saad, F., Lorde, N., Maarouf, A., et al. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0019 · Cited by 7
Visvanathan, R., Piantadosi, C., Lange, K. M., Naganathan, V., Hunter, P., Cameron, I. D., & Chapman, I. M. (2016) · The journal of nutrition health & aging · doi:10.1007/s12603-016-0689-y · Cited by 7
Eivers, S. B., & Kinsella, B. T. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.06.011 · Cited by 7
Issues Surrounding Testosterone Replacement Therapy
Schlich, C., & Romanelli, F. (2016) · Hospital Pharmacy · doi:10.1310/hpj5109-712 · Cited by 7
Williams, B. R., & Cho, J. S. (2017) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.04.006 · Cited by 7
Yalamanchi, S., & Dobs, A. S. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000435 · Cited by 7
Corona, G., Rastrelli, G., Ricca, V., & Maggi, M. (2010) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.048 · Cited by 7
Estrogens, the be-all and end-all of male hypogonadal bone loss?
Laurent, M. R., Gielen, E., & Vanderschueren, D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2865-4 · Cited by 7
Ho, C. C. K., Ho, S. E., & Das, S. (2014) · European Urology · doi:10.1016/j.eururo.2014.06.003 · Cited by 7
Late-Onset Hypogonadism in Middle-Aged and Elderly Men
Sun, A. Y., & Dimitrakoff, J. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009328 · Cited by 7
Reproductive and Nonreproductive Actions of Testosterone
Bhasin, S., & Jasuja, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65412-0 · Cited by 7
Self-citationShaikh, S., Ahmad, K., Lim, J. H., Ahmad, S. S., Lee, E. J., & Choi, I. (2025) · Pharmaceuticals · doi:10.3390/ph18091407 · Cited by 7
Becerra, C. A. G., Gallardo, M. I. A., Garcia, J. E. J., Soltero-Molinar, V., Parra-Camaño, L. F., Rivera-Rocha, M. I., Garcia-Becerra, N., & García-Gutiérrez, C. M. (2026) · International Journal of Impotence Research · doi:10.1038/s41443-026-01237-4 · Cited by 6
Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories
Iwamoto, S. J., Rothman, M. S., T'Sjoen, G. G., & Defreyne, J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad536 · Cited by 6
Gonadal status modulates large elastic artery stiffness in healthy middle-aged and older men
DuBose, L. E., Babcock, M. C., Kohrt, W. M., Stauffer, B. L., Hildreth, K. L., Walker, J., Armstrong, M. K., & Moreau, K. L. (2024) · GeroScience · doi:10.1007/s11357-024-01293-y · Cited by 6
Cardiovascular disease and testosterone therapy in male hypogonadism
de Silva, N. L., Grant, B., Minhas, S., & Jayasena, C. N. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15211 · Cited by 6
Lee, H., Hwang, E. C., Oh, C. K., Lee, S., Yu, H. S., Lim, J. S., Kim, H. W., Walsh, T. J., Kim, M. H., Jung, J. H., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.240146 · Cited by 6
Otzel, D. M., Nichols, L., Conover, C. F., MARANGI, S. A., Kura, J. R., Iannaccone, D. K., Clark, D. J., Gregory, C. M., Sonntag, C. F., Wokhlu, A., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1479264 · Cited by 6
Feng, X. G., Xia, K., Ke, Q., Deng, R., Zhuang, J., Wan, Z., Luo, P., Wang, F., Zang, Z., Sun, X., et al. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111039 · Cited by 6
The Effects of Testosterone Treatment on Cardiovascular Health
Jayasena, C. N., Ho, C. L. T., & Bhasin, S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.006 · Cited by 6
Self-citationMotsinger, L. A., Okamoto, L. L., Ineck, N. E., Udy, B. A., Erickson, C. L., Harraq, Y., Reichhardt, C. C., Murdoch, G. K., & Thornton, K. J. (2023) · Biology · doi:10.3390/biology12030446 · Cited by 6
Yu, Y., Wang, Y., Xu, L., Li, W., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1319582 · Cited by 6
Men Living With HIV and Experiencing Sexual Dysfunction: An Analysis of Treatment Options
Roberson, D. W., & Kosko, D. A. (2013) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/j.jana.2012.08.010 · Cited by 6
Serum Adiponectin Level as a Biomarker of Coronary Artery Calcification and Severe Coronary Lesions
Jover, E., Hernández‐Romero, D., Hurtado, J. A., Romero‐Aniorte, A. I., Casas, T., & Valdés, M. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.03.024 · Cited by 6
Controversial Effects of Exogenous Testosterone on Cardiovascular Diseases
Al-Khazaali, A., Arora, R. R., & Muttar, S. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000212 · Cited by 6
Enfermedades endocrinas en el adulto mayor
García, B. C. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70234-7 · Cited by 6
Testosterone deficiency and treatment in older men: definition, treatment, pitfalls
Zitzmann, M. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.96 · Cited by 6
Sex and Lifestyle Drugs: The Pursuit of the Fountain of Youth
Kim, M.-J., & Uhl, K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.263 · Cited by 6
Management of Hypogonadism in Cardiovascular Patients
Tanna, M. S., Schwartzbard, A. Z., Berger, J. S., Underberg, J. A., Gianos, E., & WEINTRAUB, H. S. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.01.011 · Cited by 6
Rishi, S., Olurinde, O., Peter, W., Sharma, M., Garcia‐Touza, M., Archana, G., Savin, V. A., Barua, R. S., Ram, S., & Thomas, W. G. (2020) · Annals of Nephrology · doi:10.36959/832/400 · Cited by 6
Sexual Dysfunction in Chronic Kidney Disease
Johansen, K. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00037-1 · Cited by 6
ORWOLL, E. S., Vanderschueren, D., & Boonen, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00032-7 · Cited by 6
Update on Testosterone Replacement Therapy in Hypogonadal Men
Leung, K. M. Y. B., Alrabeeah, K. A., & Carrier, S. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0523-9 · Cited by 6
The relationship between testosterone deficiency and frailty in elderly men
Saad, F. (2010) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.060 · Cited by 6
Bulbocavernosus muscle area as a novel marker for hypogonadism
Gupta, N., Carvajal, M. M. T., Jurewicz, M., & Gilbert, B. R. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.11.002 · Cited by 6
Epidemiology of Chronic Coronary Artery Disease
Wilson, P. W. F., & O’Donnell, C. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00001-7 · Cited by 6
The Longitudinal Effects of Expressive Writing on Victims of Relational Transgressions
Crowley, J. P., Denes, A., Makos, S., & Whitt, J. (2018) · Health Communication · doi:10.1080/10410236.2018.1431017 · Cited by 6
Alfaro, J. M. R., Castillo, A. Á., & Boza, A. S. (2020) · Revista Medica Sinergia · doi:10.31434/rms.v5i7.531 · Cited by 7
Tripathi, R., Sullivan, R. D., Fan, T. M., Mehta, R. M., Gladysheva, I. P., & Reed, G. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155450 · Cited by 6
Cannarella, R., Calogero, A. E., Condorelli, R. A., Aversa, A., & Vignera, S. L. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820966438 · Cited by 6
Jasuja, G. K., Bhasin, S., Rose, A. J., Reisman, J. I., Skolnik, A. A., Berlowitz, D. R., & Gifford, A. L. (2018) · AIDS Care · doi:10.1080/09540121.2018.1447080 · Cited by 6
Self-citationWare, W. R. (2010) · Cited by 6
Testosterone supplementation and cardiovascular risk
Corona, G., & Maggi, M. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.11.002 · Cited by 7
Testosterone and cardiovascular disease
Jones, T. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70141-x · Cited by 6
Dupree, J. M., Ramasamy, R., Kovac, J. R., Langille, G. M., & Lipshultz, L. I. (2014) · European Urology · doi:10.1016/j.eururo.2014.03.038 · Cited by 6
Is Men's Health Just a Single Letter?
Anawalt, B. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4362 · Cited by 6
Mortality Associated to Late-Onset Hypogonadism: Reasons Not to Treat With Testosterone?
Kaufman, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1103 · Cited by 6
Testosterone Replacement Therapy
Kloner, R. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416646938 · Cited by 6
Fierro Rodríguez, D. (2025) · Revista de Derecho Civil · Cited by 6
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men
Anawalt, B. D. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00254-1 · Cited by 6
Laskin, G. R., Steiner, J. L., Ayers-Creech, W. A., Rossetti, M. L., Dunlap, K. R., Vied, C., Lee, C., Greene, N. P., Fix, D. K., Laitano, O., et al. (2025) · Function · doi:10.1093/function/zqaf030 · Cited by 6
Kim, G. Y., Conduit, C., O’Haire, S., Chong, C. Y., Baenziger, O., Lewin, J. H., Thomas, B., Lawrentschuk, N., Stockler, M. R., Olver, I., et al. (2024) · Basic and Clinical Andrology · doi:10.1186/s12610-024-00230-5 · Cited by 5
Sex Hormone Supplementation and Cardiovascular Disease Risk
Kampka, Z., Balwierz, M., & Wybraniec, M. T. (2026) · Medicina · doi:10.3390/medicina62010134 · Cited by 5
Metabolic Messengers: testosterone
Mauvais‐Jarvis, F., & Bhasin, S. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01431-6 · Cited by 6
Self-citationSjöström, K., Mount, J., Klocker, A., & Arthurson, V. (2022) · Veterinary Record Open · doi:10.1002/vro2.48 · Cited by 5
Huo, Y., Wang, W., Zhang, J., Xu, D., Bai, F., & Gui, Y. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02178-1 · Cited by 5
Trumble, B. C., Negrey, J. D., Koebele, S. V., Thompson, R. C., Wann, L. S., Allam, A. H., Beheim, B., Sutherland, M. L., Sutherland, J. D., Rodríguez, D. E., et al. (2023) · Evolution Medicine and Public Health · doi:10.1093/emph/eoad039 · Cited by 5
Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men
Krishnan, S., Aldana-Bitar, J., Golub, I. S., Ichikawa, K., Shabir, A., Bagheri, M., Hamidi, H., Benzing, T., Kianoush, S., & Budoff, M. J. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.02.015 · Cited by 5
Association between Drug Therapy and Risk of Incident Frailty: A Systematic Review
Thanapluetiwong, S., Chattaris, T., Shi, S., Park, C. M., Sison, S. D. M., & Kim, D. (2024) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.24.0034 · Cited by 5
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
Edison, M. A., Kirby, M. G., & Hackett, G. I. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.250086 · Cited by 5
Hypogonadism and Testosterone Therapy
Maganty, A., Osterberg, E. C., & Ramasamy, R. (2014) · American Journal of Men s Health · doi:10.1177/1557988314540933 · Cited by 5
Mori, H., & Niwa, M. (2014) · The Japanese Journal of Nutrition and Dietetics · doi:10.5264/eiyogakuzashi.72.12 · Cited by 5
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 5
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
Mukherjee, D., Sen, K., Gupta, S., Chowdhury, P. D., Majumder, S., & Guha, P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.85852 · Cited by 5
Sex Hormones and Their Impact on Cardiovascular Health
Jesus, S. D., Gianos, E., McNally, S. T., Scantlebury, D. C., & Rosen, S. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819369-3.00029-0 · Cited by 8
Groepenhoff, F., Benavente, E. D., Boltjes, A., Timmerman, N., Waissi, F., Hartman, R. J. G., Onland‐Moret, N. C., Pasterkamp, G., & den Ruijter, H. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.693351 · Cited by 5
Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101626 · Cited by 6
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
